Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Randomized clinical trial… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome

Artikel i vetenskaplig tidskrift
Författare Bani Ahluwalia
Maria K Magnusson
Lena Böhn
Stine Störsrud
F. Larsson
O. Savolainen
A. Ross
Magnus Simrén
Lena Öhman
Publicerad i Neurogastroenterology and Motility
ISSN 1350-1925
Publiceringsår 2020
Publicerad vid Institutionen för biomedicin
Institutionen för medicin
Språk en
Länkar dx.doi.org/10.1111/nmo.13860
Ämnesord Aloe, fecal metabolites, gastrointestinal microbiota, gastrointestinal, symptoms, irritable bowel syndrome, prebiotic, placebo-controlled trial, double-blind, alternative medicine, vera gel, complementary, inulin, avh200(r), system, Gastroenterology & Hepatology, Neurosciences & Neurology
Ämneskategorier Gastroenterologi, Neurovetenskaper

Sammanfattning

Background Aloe barbadensis Mill. (Aloe) with potential prebiotic effects has been suggested to reduce symptoms in patients with irritable bowel syndrome (IBS). We therefore aimed to determine the effects of an Aloe extract on symptoms of IBS, and evaluate whether effects may be mediated by fecal microbiota and metabolites in a randomized, double-blind, controlled trial. Methods Patient with IBS diagnosed according to the ROME III criteria (all subtypes), received Aloe or control treatment (inulin) for 4 weeks. IBS Symptom Severity Score (IBS-SSS) was assessed, and fecal samples collected before and at end of treatment. Fecal microbiota composition and metabolomic profile were determined. Key results In total, 160 IBS patients completed the study. The overall severity of IBS symptoms was reduced in both Aloe and control treatment groups (P < .001, both groups, comparing baseline vs end of treatment), without difference between groups (P = .62). The frequency of responders (IBS-SSS reduction >= 50) did not differ between Aloe treatment (n = 33, 39%) and control (n = 34, 45%) (P = .49). However, fecal microbiota and metabolite profiles differed between Aloe, but not control treatment responders and non-responders both before and after treatment. Conclusion In a mixed group of IBS patients, Aloe was not superior to control treatment, although it showed potential to reduce IBS symptom severity in subsets of IBS patients which could be predicted by fecal microbiota and metabolite profiles. ClinicalTrials.gov no: NCT01400048.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?